MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas

Mod Pathol. 2002 Nov;15(11):1172-80. doi: 10.1097/01.MP.0000032534.81894.B3.

Abstract

The MAL mRNA was initially identified during T-cell development and was later found in myelin-forming cells and certain polarized epithelial cell lines. It encodes a proteolipid believed to participate in membrane microdomains stabilization, transport machinery and signal transduction. Using a differential display reverse-transcription approach, we identified MAL as a distinct molecular marker of primary mediastinal large B-cell lymphoma compared with nonmediastinal diffuse large B-cell lymphomas. In the present study, we used immunohistochemistry to extend MAL expression analysis to normal lymphoid tissues; to 185 lymphomas representing most B, T, and Hodgkin lymphoma entities; and to the primary mediastinal large B-cell lymphoma derived B-cell line MedB-1. In addition, B and T cells from peripheral blood, tonsil, and spleen were analyzed by flow cytometry. Our results show that MAL is highly expressed in thymocytes, in a large percentage of peripheral CD4 T cells, and in a lower proportion of CD8 peripheral T cells. In the normal B-cell compartment, MAL expression appears to be restricted to a minor subpopulation of thymic medullary B cells and to occasional mature plasma cells located in the interfollicular areas of tonsil and lymph nodes. Among B-cell lymphomas (n = 110), MAL expression in tumor cells was observed in 21/33 primary mediastinal large B-cell lymphomas (70%) and in 3/5 plasmacytoma/myeloma, but not in all other B-cell lymphomas with the exception of 1/33 nonmediastinal diffuse large B-cell lymphomas. The MedB-1 B-cell line was also MAL positive. Among T-cell neoplasms, MAL was highly expressed in lymphoblastic tumors (5/6), whereas mature T-cell lymphomas were essentially MAL negative (27/28). Among 41 Hodgkin lymphomas, 3 nodular-sclerosing cases with mediastinal involvement showed MAL-positive Reed Sternberg cells. In conclusion, this study further supports thymic B cells as the putative normal counterpart of primary mediastinal large B-cell lymphomas and supports MAL as a distinct molecular marker of this lymphoma subtype among diffuse large B-cell lymphomas.

MeSH terms

  • Antigens, CD / analysis
  • Biomarkers, Tumor / analysis
  • CD79 Antigens
  • Flow Cytometry
  • Humans
  • Immunohistochemistry / methods
  • Lymph Nodes / chemistry
  • Lymph Nodes / pathology
  • Lymphocytes / chemistry
  • Lymphoma, B-Cell / metabolism
  • Lymphoma, B-Cell / pathology*
  • Mediastinal Neoplasms / metabolism
  • Mediastinal Neoplasms / pathology*
  • Membrane Transport Proteins*
  • Myelin Proteins*
  • Myelin and Lymphocyte-Associated Proteolipid Proteins
  • Palatine Tonsil / chemistry
  • Palatine Tonsil / pathology
  • Proteolipids / biosynthesis*
  • Receptors, Antigen, B-Cell / analysis
  • Spleen / chemistry
  • Spleen / pathology
  • Thymus Gland / chemistry
  • Thymus Gland / pathology

Substances

  • Antigens, CD
  • Biomarkers, Tumor
  • CD79 Antigens
  • CD79A protein, human
  • MAL protein, human
  • Membrane Transport Proteins
  • Myelin Proteins
  • Myelin and Lymphocyte-Associated Proteolipid Proteins
  • Proteolipids
  • Receptors, Antigen, B-Cell